TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Laboratorios Farmaceuticos Rovi ( (ES:ROVI) ) has issued an update.
ROVI’s Board of Directors has approved the preparation of the company’s annual and consolidated financial accounts for the fiscal year ending December 31, 2024. They have also proposed a dividend distribution of 0.9351 euros per share, representing about 35% of the consolidated net profit. Additionally, the company has approved the publication of several key reports for 2024, including the Annual Financial Report, Corporate Governance Report, and Directors’ Remuneration Report, which will be accessible on their corporate website.
More about Laboratorios Farmaceuticos Rovi
Laboratorios Farmacéuticos ROVI is a pharmaceutical company involved in the development and production of a range of pharmaceutical products. The company focuses on providing innovative health solutions and operates within the pharmaceutical industry, catering to various healthcare needs.
YTD Price Performance: -12.66%
Average Trading Volume: 3,521
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €2.77B
See more insights into ROVI stock on TipRanks’ Stock Analysis page.